SF is a 50-year-old woman, counseled about the therapeutic use of psilocybin by her neurologist, who has participated in ...

The cortex refers to the outermost layer of the cerebral hemispheres or cerebrum. The cerebral cortex in humans is folded into gyri and consists of six horizontal layers of neurons, with distinct ...

Voyager Therapeutics leverages its TRACER platform for targeted gene therapies, focusing on challenging CNS diseases like Alzheimer ... (other than from Seeking Alpha). I have no business ...

announced new data from its IM-PROVE I Phase 2a clinical trial showing that six doses of imdusiran, the company’s RNAi therapeutic candidate, and 24 weeks of pegylated interferon alfa-2a ...

(Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today ... the way for a Phase 2a proof-of-concept ...

With positive results, Phase 2a proof-of-concept study expected to ... company addressing diseases of the central nervous system (CNS), today announced the initiation of dosing in a Phase 1 ...

Objective To determine whether a chemokine receptor type 2 antagonist, DMX-200 (repagermanium), in combination with an angiotensin receptor blocker, candesartan, improves clinical outcomes in people ...

First things first; Neurogene’s background: Neurogene develops genetic medicines for CNS diseases ... for it (other than from Seeking Alpha). I have no business relationship with any company ...

For the first time, the British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) have collaborated to develop ...